Cited by 1,070Herpesvirus Infections and TreatmentsCytomegalovirus and herpesvirus researchVirology and Viral Diseases

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Open access

Cunningham, Anthony L., Lal, Himal, Kovac, Martina, Chlibek, Roman, Hwang, Shinn-Jang, Díez-Domingo, Javier, Godeaux, Olivier, Levin, Myron J., McElhaney, Janet E., Puig-Barberà, Joan, Vanden Abeele, Carline, Vesikari, Timo, Watanabe, Daisuke, Zahaf, Toufik, Ahonen, Anitta, Athan, Eugene, Barba-Gomez, Jose F., Campora, Laura, de Looze, Ferdinandus, Downey, H. Jackson, Ghesquiere, Wayne, Gorfinkel, Iris, Korhonen, Tiina, Leung, Edward, McNeil, Shelly A., Oostvogels, Lidia, Rombo, Lars, Smetana, Jan, Weckx, Lily, Yeo, Wilfred, Heineman, Thomas C.·2016·New England Journal of Medicine

DOI 10.1056/nejmoa1603800

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (HZ/su) containing recombinant varicella-zoster virus glycoprotein E and the AS01B adjuvant system was associated with a risk of herpes zoster that was 97.2% lower than that associated with placebo. A second trial was performed concurrently at the same sites and examined the safety and efficacy of HZ/su in adults 70 years of age or older (ZOE-70). METHODS: This randomized, placebo-controlled, phase 3 trial was conducted in 18 countries and involved adults 70 years of age or older. Participants received two doses of HZ/su or placebo (assigned in a 1:1 ratio) administered intramuscularly 2 months apart. Vaccine efficacy against herpes zoster and postherpetic neuralgia was assessed in participants from ZOE-70 and in participants pooled from ZOE-70 and ZOE-50. RESULTS: In ZOE-70, 13,900 participants who could be evaluated (mean age, 75.6 years) received either HZ/su (6950 participants) or placebo (6950 participants). During a mean follow-up period of 3.7 years, herpes zoster occurred in 23 HZ/su recipients and in 223 placebo recipients (0.9 vs. 9.2 per 1000 person-years). Vaccine efficacy against herpes zoster was 89.8% (95% confidence interval [CI], 84.2 to 93.7; P<0.001) and was similar in participants 70 to 79 years of age (90.0%) and participants 80 years of age or older (89.1%). In pooled analyses of data from participants 70 years of age or older in ZOE-50 and ZOE-70 (16,596 participants), vaccine efficacy against herpes zoster was 91.3% (95% CI, 86.8 to 94.5; P<0.001), and vaccine efficacy against postherpetic neuralgia was 88.8% (95% CI, 68.7 to 97.1; P<0.001). Solicited reports of injection-site and systemic reactions within 7 days after injection were more frequent among HZ/su recipients than among placebo recipients (79.0% vs. 29.5%). Serious adverse events, potential immune-mediated diseases, and deaths occurred with similar frequencies in the two study groups. CONCLUSIONS: In our trial, HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older. (Funded by GlaxoSmithKline Biologicals; ZOE-50 and ZOE-70 ClinicalTrials.gov numbers, NCT01165177 and NCT01165229 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1603800

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The burden of disease in older people and implications for health policy and practice
Prince, M. J., Wu, F., Guo, Y., Gutiérrez‐Robledo, L. M., O'Donnell, M. J., Sullivan, R. J., & Yusuf, S. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61347-7 · Cited by 2,473
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S., Gershon, A. A., Davis, L. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051016 · Cited by 2,412
Self-citation
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Self-citation
Systematic review of incidence and complications of herpes zoster: towards a global perspective
Kawai, K., Gebremeskel, B. G., & Acosta, C. J. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004833 · Cited by 943
A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction
Yawn, B. P., Saddier, P., Wollan, P. C., Sauver, J. L. S., Kurland, M. J., & Sy, L. S. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1341 · Cited by 866
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
Herpes Zoster
Cohen, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmcp1302674 · Cited by 737
Postherpetic Neuralgia
Johnson, R. W., & Rice, A. S. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmcp1403062 · Cited by 575
The incidence of herpes zoster in a United States administrative database
Insinga, R. P., Itzler, R. F., Pellissier, J. M., Saddier, P., & Nikas, A. A. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0150.x · Cited by 490
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Mechelen, M. V. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 318

Flagged first, then by citations

Show all 31 references

Research works printed but not linked: 3

Harpaz R, 2008, MMWR Recomm Rep, 57, 1
Chen N, 2014, Cochrane Database Syst Rev, CD006866
2011, MMWR Morb Mortal Wkly Rep, 60, 1528

Sorted by citations

Items 701–800 of 1,000

Herpes Zoster Vaccination: An Urgent Priority
Galvis, V., Tello, A., Carreño, N. I., Berrospi, R. D., Niño, C. A., & Rey, J. J. (2018) · Cornea · doi:10.1097/ico.0000000000001771 · Cited by 3
Can patients on methotrexate receive live vaccines?
Pourcher, V. (2018) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.12.008 · Cited by 3
Incidence of Microbial Infections in English UK Biobank Participants: Comparison with the General PopulationPreprint
Hilton, B., Wilson, D. J., O’Connell, A. M., Ironmonger, D., Rudkin, J., Allen, N. E., Oliver, I., & Wyllie, D. H. (2020) · medRxiv · doi:10.1101/2020.03.18.20038281 · Cited by 3
An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged micePreprint
Borriello, F., Nanishi, E., Seo, H., O’Meara, T. R., McGrath, M. E., Saito, Y., Haupt, R. E., Chen, J., Diray‐Arce, J., Song, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.09.459664 · Cited by 3
Estado actual del herpes zóster y las nuevas perspectivas para su prevención
Molero, J., Ortega, J., Montoro, I., & McCormick, N. (2024) · Vacunas · doi:10.1016/j.vacun.2023.12.005 · Cited by 2
Varicella, measles, and mumps
Moss, W. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-79525-8.00033-0 · Cited by 2
Post-Shingrix Vaccination Guillain-Barré Syndrome Presentation in the Emergency Department: A Case Report and Literature Review
Drmota, J., Quader, K. S., & Naeem, S. (2025) · Cureus · doi:10.7759/cureus.77777 · Cited by 2
The Potential Impact of Increased Recombinant Zoster Vaccine Uptake in Older Adults Worldwide
Giannelos, N., Curran, D., Matthews, S., Carrico, J., & Cunningham, A. L. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-025-01161-y · Cited by 2
Self-citation
Long-term immunogenicity of a live attenuated herpes zoster vaccine in patients with systemic lupus erythematosus
Mok, C. C., Chan, K. L., & Tse, S. M. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127365 · Cited by 2
Awareness and acceptability of herpes zoster vaccination in people living with HIV
Motet, C., Libois, A., Martin, C., & Dauby, N. (2025) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2025.103143 · Cited by 2
Antibody Responses Following Primary Immunization with the Recombinant Herpes Zoster Vaccine (Shingrix®) in VZV Seronegative Immunocompromised Adults
Wessely, A., Zwazl, I., Poturica, M., Weseslindtner, L., Kundi, M., Wiedermann, U., & Wagner, A. (2025) · Vaccines · doi:10.3390/vaccines13070737 · Cited by 2
Impact of Pregnancy and the Postpartum Period on Noninfectious Uveitis Flare-Ups
Xu, X., Ray, I., Tang, E., Arnold, B. F., & Acharya, N. R. (2025) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2025.2532826 · Cited by 2
Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease
Tseng, H. F., Sy, L. S., Rayens, E. A., Ackerson, B. K., Ku, J. H., Wu, J., Luo, Y., Cheng, Y., Patel, A. R., Solano, Z., et al. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2576981 · Cited by 2
Preventive Effectiveness of Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors
Tabata, Y., Tanimura, S., Kitano, A., Shibata, Y., Nakagawa, I., Matsuhashi, M., Shimizu, M., Tanimura, K., & Koike, T. (2025) · Internal Medicine · doi:10.2169/internalmedicine.6154-25 · Cited by 2
A novel calcium influx inducer and a TLR7 agonist are synergistic co-adjuvants that enhance cross-reactive immunity against influenza in young and aged mice
Yokoyama, Y., Yao, S., Cozza, R., Gil, F., McLaughlin, I. J., Quiroz, P. Y. A., Brown, T. H. T., Shukla, N. M., Chan, M., Messer, K. S., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2025.128189 · Cited by 2
Cardiovascular Outcomes Following Herpes Zoster Vaccination: A Systematic Review and Meta-Analysis
Maniya, M. T., Farid, A. A. M., Abid, H., Abbasi, B., Afzal, S., Afzaal, U., Bibi, M., Fatima, R., Khalid, H., Kumari, N., et al. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001243 · Cited by 2
Herpes Zoster of the Maxillary Division of the Trigeminal Nerve Presenting as Endodontic Post-treatment Pain: Case Report and Review of the Literature
Lin, J., Jalali, P., Teixeira, F. B., Lin, Y., Allen, S. P., Hanson, J., & Wang, F. (2026) · Journal of Endodontics · doi:10.1016/j.joen.2026.03.005 · Cited by 2
Long-term immunogenicity and safety of RZV primary vaccination and revaccination in kidney transplant recipients
Hutton, M. M., Vink, P., Kuxhausen, A., Tsang, M., Fructuoso, A. S., Robberechts, T., Carillo, R. A. P., Park, J. B., Ortiz, F., Kumar, D., et al. (2026) · Journal of Infection · doi:10.1016/j.jinf.2026.106758 · Cited by 2
Cost-effectiveness of recombinant zoster vaccine (Shingrix) in US adults aged ≥50 years
Yue, Y., Le, P., Adekunle, O. A., Tran, H. T., & Rothberg, M. B. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.05.024 · Cited by 2
Combination adjuvants: clinical value and mechanisms of action
Madelon, N., & Didierlaurent, A. M. (2026) · Current Opinion in Virology · doi:10.1016/j.coviro.2026.101564 · Cited by 2
The health threats to people with asthma through asthma‐associated infectious disease comorbidities are largely under‐recognized
Juhn, Y. J. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12650 · Cited by 2
What are the new vaccination recommendations for herpes zoster?
Mospan, C. M., & Colvin, N. N. (2018) · JAAPA · doi:10.1097/01.jaa.0000545079.16968.0e · Cited by 2
Alternative Approach to Varicella Zoster Virus Prevention in a Child with Lymphopenia
Cortesi, M., & Badolato, R. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01091-7 · Cited by 2
Translatability scoring in prospective and retrospective COVID drug development cases
Wendler, A., & Wehling, M. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03517-0 · Cited by 2
Zoster Vaccines
Levin, M. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00066-9 · Cited by 2
Self-citation
Vacunación frente al virus del herpes zóster
Marco, J. J. G., Martín, S. M., Herce, P. A., Miranda, A. P. J., & Hernández, C. S. (2023) · Atención Primaria · doi:10.1016/j.aprim.2023.102710 · Cited by 2
Rapport 23-25. Vaccination des seniors
Buisson, Y., Bègué, P., & Michel, J. (2023) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2023.12.010 · Cited by 2
Tree‐temporal scan statistics for safety signal detection in vaccine clinical trials
Haguinet, F., Tibaldi, F. S., Dessart, C., & Bate, A. (2024) · Pharmaceutical Statistics · doi:10.1002/pst.2391 · Cited by 2
Patient Experience of Herpes Zoster Disease in Argentina: Validation of a Health-Related Quality of Life Conceptual Model
Belizán, M., Augustovski, F., Bardach, A., Pinto, T., Villarejo, A., Lazo, E., Cordo, M. V., & Oorschot, D. V. (2024) · Value in Health Regional Issues · doi:10.1016/j.vhri.2024.101044 · Cited by 2
Vaccines, Vaccinations, and the Re-emergence of and Vaccine-Preventable Diseases
Majstorović, M., & Weatherspoon, D. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-64611-9_7 · Cited by 2
Schutzimpfungen bei CKD
Hohenstein, B., Feldkamp, T., & Girndt, M. (2024) · Die Nephrologie · doi:10.1007/s11560-024-00807-1 · Cited by 2
Varicella-zoster Virus Reactivation with Severe Pneumonia Following Convalescence from Coronavirus Disease: A Case Report and Literature Review
Tome, R., Arima, S., Akamine, M., Hashioka, H., Arakaki, W., Kami, W., Nabeya, D., Ideguchi, S., Nakamura, H., Kinjo, T., et al. (2025) · Internal Medicine · doi:10.2169/internalmedicine.4932-24 · Cited by 2
Post-vaccinal seronegative autoimmune encephalitis following recombinant zoster vaccination in two immunocompetent patients
Madani, T. A., Khoja, A. A., Abuzinadah, A. R., Abbas, G. M., Alotaibi, A. A., Alshehri, Z. I., & Madani, S. T. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102713 · Cited by 2
A novel adjuvant system BK-02 with CpG2006 and MF59 enhances the immunogenicity of a herpes zoster subunit vaccine
Wang, Z., Guo, Y., Tang, X., Sun, Y., Wu, T., Peng, H., Wang, C., Su, W., Jiang, C., Zang, Y., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1641109 · Cited by 2
Effektivität der Herpes-zoster-Impfung bei über 70-Jährigen
Salzberger, B., & Nitschmann, S. (2017) · Der Internist · doi:10.1007/s00108-017-0222-3 · Cited by 2
Quoi de neuf en thérapeutique dermatologique ?
Ezzedine, K. (2016) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/s0151-9638(18)30048-6 · Cited by 2
Vaccination for Patients with Rheumatic Diseases in the Era of Biologics
Han, S. H. (2018) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2018.25.2.100 · Cited by 2
The Economic Impact of Herpes Zoster Vaccine Disparities in Elderly United States Blacks
Wingate, L. T., Stubbs, K., Ahmed, I., Mayaka, R. K., Maneno, M. K., Ettienne, E. B., Elekwachi, O., & Clarke-Tasker, V. A. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15102128 · Cited by 2
Systemic Lupus Erythematosus and Infections
Devlin, A., & Shmerling, R. H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801917-7.00045-0 · Cited by 2
Programmatische gordelroosvaccinatie: nu nog niet
Opstelten, W. (2017) · Huisarts en Wetenschap · doi:10.1007/s12445-017-0099-3 · Cited by 2
UK experience of herpes zoster vaccination can inform varicella zoster virus policies
Ogunjimi, B., & Beutels, P. (2017) · The Lancet Public Health · doi:10.1016/s2468-2667(17)30245-1 · Cited by 2
Varicella and Herpes Zoster
Dudley, M. Z., Salmon, D. A., Halsey, N. A., Orenstein, W. A., Limaye, R. J., O’Leary, S. T., & Omer, S. B. (2018) · Springer eBooks · doi:10.1007/978-3-319-94694-8_18 · Cited by 2
Herpes Zoster Vaccines
Cunningham, A. L., Levin, M. J., & Heineman, T. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55435-0.00004-5 · Cited by 2
Self-citation
Zosterimpfung unter Biologikatherapie
Jahn, S., Diamanti, E., Heller, T., Papageorgiou, A., & Herbst, M. (2021) · ästhetische dermatologie & kosmetologie · doi:10.1007/s12634-021-1579-9 · Cited by 2
Disorders of the Peripheral Nervous System
Vitrikas, K., & Hurst, N. (2020) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_74-2 · Cited by 2
Immunosenescence Modulation by Vaccination
McElhaney, J. E. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_71 · Cited by 2
Self-citation
Latent CMV makes older adults less naïve
Pawelec, G. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103887 · Cited by 2
Effects of Aging on Human Toll-Like Receptor Function
Shaw, A. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-64597-1_98-1 · Cited by 3
Recommendations of the Spanish Group on Crohn’s Disease and Ulcerative Colitis on the importance, screening and vaccination in inflammatory bowel disease patients
Ferreiro‐Iglesias, R., Piqueras, M., Ricart, E., Sempere, L., Roca, M., de Carpi, J. M., Benítez, O., Zabana, Y., Mañosa, M., Rodríguez‐Moranta, F., et al. (2022) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2022.03.004 · Cited by 2
Herpes zoster vaccination recommendations ofthe group of experts of the Polish Society of Vaccinology,the Polish Society of Family Medicine, the Polish Societyof Dermatology, the Polish Association for the Studyof Pain and the Polish Neurological Society
Kuchar, E. P., Rudnicka, L., Kocot-Kępska, M., Nitsch-Osuch, A. S., Rejdak, K., Wysocki, J., Biesiada, A. M., Ledwoch, J., Wawrzuta, D., Mastalerz–Migas, A., et al. (2023) · Ból · doi:10.5604/01.3001.0053.7732 · Cited by 2
Vaccines, Vaccine-Preventable Diseases, and Frailty
Pott, H., & Andrew, M. K. (2024) · Springer eBooks · doi:10.1007/978-3-031-57361-3_46 · Cited by 2
The alpha-herpesviridae in dermatology
Hayderi, L. E., Rübben, A., & Nikkels, A. (2017) · Der Hautarzt · doi:10.1007/s00105-016-3920-1 · Cited by 2
Immunization update 2018
Angelo, L. B. (2018) · Pharmacy Today · doi:10.1016/j.ptdy.2018.08.030 · Cited by 2
Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence
Good, C. B., Parekh, N., & Hernandez, I. (2018) · BMC Medicine · doi:10.1186/s12916-018-1231-3 · Cited by 2
Novel Technologies to Improve Vaccines for Older Adults
Laupèze, B., der Most, R. G. V., & Giudice, G. D. (2020) · Interdisciplinary topics in gerontology and geriatrics · doi:10.1159/000504485 · Cited by 2
When wrinkles appear on the immune system can it be reversed?
Sibaii, H., El-Zayat, S. R., & Khalil, M. (2020) · European Cytokine Network · doi:10.1684/ecn.2020.0441 · Cited by 4
Alphaherpesvirus Vaccines
Aschner, C. B., & Herold, B. C. (2020) · Caister Academic Press eBooks · doi:10.21775/9781913652555.10 · Cited by 2
A unique spliced varicella-zoster virus latency transcript represses expression of the viral transactivator gene 61Preprint
Depledge, D. P., Ouwendijk, W. J. D., Sadaoka, T., Braspenning, S. E., Mori, Y., Cohrs, R. J., Verjans, G. M. G. M., & Breuer, J. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/174797 · Cited by 2
Which shingles vaccine for older adults?
Le, P. (2018) · BMJ · doi:10.1136/bmj.k4203 · Cited by 2
Herpes Zoster Subunit Vaccination for Renal Transplant Recipients
Cheng, M. P., Quach, C., & Marty, F. M. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz494 · Cited by 2
[Prevention by vaccination of adult patients with pulmonary diseases].
Dodt, C., Pletz, M. W., & Kolditz, M. (2021) · PubMed Central · doi:10.1007/s10405-021-00402-4 · Cited by 1
Nanotechnology-based approaches against COVID-19
Abolmaali, S. S., Alimardani, V., Farahavar, G., Najafi, H., Shafiee, M., Tanideh, N., Tamaddon, A. M., & Ahadian, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90792-7.00012-9 · Cited by 1
State of the art in herpes zoster and new perspectives in its prevention
Molero, J., Ortega, J., Montoro, I., & McCormick, N. (2024) · Vacunas (English Edition) · doi:10.1016/j.vacune.2024.05.001 · Cited by 1
Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged ≥50 years
Kluberg, S. A., Simon, A. L., Alam, S. M., Peters, A., Horgan, C. E., Li, D., Moyneur, É., Messenger‐Jones, E., Platt, R. G., McMahill‐Walraven, C. N., et al. (2024) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2024.152518 · Cited by 1
Prescription opioids following herpes zoster: An observational study among insured adults, United States, 2007-2021
Dooling, K. L., Leung, J. W. T., & Bohm, M. K. (2024) · Journal of Opioid Management · doi:10.5055/jom.0845 · Cited by 1
Vaccination Strategies for a Liver Transplant Recipient
Sahu, M., Praharaj, D. L., & Bhadoria, A. S. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.102421 · Cited by 1
Immune Response to an Adjuvanted Recombinant Zoster Vaccine in Japanese Patients with Rheumatoid Arthritis Receiving Upadacitinib (End Zoster-J Study): Study Protocol for an Exploratory Parallel Triple-Arm Prospective Trial
Watanabe, R., Fujii, H., Imai, T., Furusawa, Y., Katsushima, M., Fukumoto, K., Yamada, Y., Mamoto, K., Okano, T., Yamada, S., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237321 · Cited by 1
A prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the recombinant zoster vaccine in Chinese adults ≥50 years of age
Pang, X., Spence, O., Parmar, N., Wang, J., Zhou, T., Guo, X. J., Colliou, A., Sarang, S. P., Yousefi, M., & Yun, H. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2439031 · Cited by 1
An Exploratory Investigation of Representations of Herpes Zoster and Adjuvanted Recombinant Herpes Zoster Vaccination in a Sample of Fragile Adults in Italy
Caro, F. D., Pecoraro, N., Capunzo, M., Caruccio, S., Caggiano, F., Cersosimo, G., Costantino, M., Longanella, W., Malatesta, F., Tomeo, M., et al. (2025) · Pathogens · doi:10.3390/pathogens14020145 · Cited by 1
Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial
Naficy, A., Chugh, Y., Tariq, M., Hawksworth, H., Sankhe, L., & Mwakingwe-Omari, A. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126819 · Cited by 1
Antibody Titer Against Varicella Zoster Virus and Recombinant Varicella Zoster Vaccine in Hemodialysis Patients: What We Know, What We Should Know
Martino, F. K., Stefanelli, L. F., Cacciapuoti, M., Bettin, E., Scaparrotta, G., Gobbi, L., Prete, D. D., Calò, L. A., & Nalesso, F. (2025) · Life · doi:10.3390/life15040621 · Cited by 1
Cost-Utility and Budget Impact Analyses of Herpes Zoster Vaccines in Patients With Human Immunodeficiency Virus in Thailand
Kulthanachairojana, N., Hemapanpairoa, J., Santhaveesook, C., Piboonsatsanasakul, P., & Fueymee, A. (2025) · Value in Health Regional Issues · doi:10.1016/j.vhri.2025.101119 · Cited by 1
Lessons from the past: what does the future of clinical management of infection after solid organ transplantation look like?
Fernández‐Ruiz, M., & Aguado, J. M. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2513461 · Cited by 1
Bibliometric analysis and visualization mapping of herpes zoster vaccine publications from 1999 to 2024
Gao, W., Gao, D., Li, L., Li, J., Yao, X., & Zhang, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1516450 · Cited by 1
Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization
Martino, E. A., Vigna, E., Bruzzese, A., Amodio, N., Lucia, E., Olivito, V., Labanca, C., Caserta, S., Mendicino, F., Morabito, F., et al. (2025) · European Journal Of Haematology · doi:10.1111/ejh.70049 · Cited by 1
Influence of meteorological conditions on herpes zoster occurrence: a retrospective cohort study
Ochal, M., Lewczuk, K. G., Dragańska, E., Cymes, I., & Romaszko, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1643828 · Cited by 1
Efficacy and safety of bloodletting therapy for acute herpes zoster: a systematic review and meta-analysis
Wu, D., Jiang, Y., Wu, Q., Jin, Y., Wang, C., Guan, L., & Shao, W. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1674245 · Cited by 1
Demographic and Clinical Characteristics of Patients Vaccinated Against Herpes Zoster in a Primary Care Setting in Spain: A Retrospective Study
Blanc-Rodriguez-Arias, J. M., Sanz, I. J., Hernández‐Barrera, V., Álvaro‐Meca, A., Torres-Ramos, M., & de Miguel, Á. G. (2025) · Vaccines · doi:10.3390/vaccines13101069 · Cited by 1
Herpes Zoster Frequency and Adjuvanted Recombinant Zoster Vaccination after Allogeneic Hematopoietic Cell Transplantation
Hall, V. G., Chiarello, C., Remberger, M., Kumar, D., Pašić, I., Kim, D. D. H., Kumar, R., Viswabandya, A., Michelis, F. V., Law, A., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.10.028 · Cited by 1
Vaccination in Patients with Cardiovascular Disease: A Case-Based Approach and Contemporary Review
Sedrak, P., Dounaevskaia, V., Mancini, G. B. J., Zieroth, S. R., McKelvie, R. S., Chiu, W., Bewick, D. J., Ducharme, A., Mansour, S., Lepage, S., et al. (2025) · CJC Open · doi:10.1016/j.cjco.2025.09.004 · Cited by 1
Potent and Long‐Lasting Immunogenicity Generated by LNP‐mRNA gE Antigen Against Varicella Zoster Virus via an AI‐Assisted Pipeline
Dong, K., Liu, F., Wang, D., Li, Y., Zhang, M., Zhou, Y., & Song, G. (2025) · Advanced Science · doi:10.1002/advs.202510913 · Cited by 1
Immunogenicity of a Recombinant Zoster Vaccine (gE/BFA01) in Mice
Quan, Y., Luo, S., Wu, S., Wang, K., Hu, L., Yihuan, H. A. O., Xu, K., & Liu, Y. (2025) · Viruses · doi:10.3390/v18010053 · Cited by 1
TLR9 and STING agonists adjuvanted varicella-zoster virus glycoprotein E induced a potent and durable nasal vaccine response
Yang, J., Lin, P.-Y., Tseng, J., Imana, Z. N., Liu, Y., Tien, C.-F., Su, Y.-Y., Tsai, W.-T., Su, Y.-Y., Chen, J. W., et al. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2615532 · Cited by 1
Liposome-mediated simvastatin in vaccine adjuvants: Its application and mechanism
Chen, Z., Xia, Z., Chen, L., Nie, Q., Gong, W., Cao, W., Wang, X., Zou, Y., Zhang, S., Yang, Y., et al. (2026) · Molecular Immunology · doi:10.1016/j.molimm.2026.01.002 · Cited by 1
BC02-adjuvanted varicella-zoster virus glycoprotein E subunit vaccine overcomes immunosenescence to induce robust neutralizing antibodies and multifunctional T-cell immunity in seropositive aged murine models
Li, J., Li, X., Yang, Y., Fu, L., Du, W., Wei, J., Su, K., Su, C., Shen, X., Wang, G., et al. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2617728 · Cited by 1
Epidemiology and risk factors of postherpetic neuralgia worldwide: protocol for a systematic review and meta-analysis
Liao, X., Xu, S., Wang, Y., & Zheng, B. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-104637 · Cited by 1
A self-assembling ferritin nanoparticle-based trivalent vaccine of gB/gE/gH elicits potent immune responses against varicella-zoster virus
Deng, J., Liu, Y., Lin, Y., Chen, T., Feng, L., Pu, Z., Liu, J., Zhang, X., Wu, S., Yuan, J., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151043 · Cited by 1
Guillain–Barré Syndrome Following Recombinant Zoster Vaccine in US Medicare Adults Age 65 Years or Older
dosReis, S., Chiang, Y.-Y., Amill‐Rosario, A., Lee, H. H., Johnson, A. M., Ryan, K., Oraichi, D., Seifert, H., Yun, H., Gamble, S., et al. (2026) · Drug Safety · doi:10.1007/s40264-026-01658-6 · Cited by 1
Vaccination in systemic lupus erythematosus
Mok, T. C., & Mok, C. C. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2663637 · Cited by 1
Safety and Immunogenicity of 1 or 2 Additional Doses of the Adjuvanted Recombinant Zoster Vaccine Administered 5–6 Years After Primary Vaccination in Adults ≥50 Years
León, R., Díez-Domingo, J., Andrews, C., da Cunha, C. A., Choo, E. J., David Shu Cheong, H. U. I., Cunningham, A. L., Eto, T., Icardi, G., McNeil, S., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag282 · Cited by 1
Self-citation
Targeting Age-Associated Immune Senescence via Nanoparticle-Based Metabolic Reprogramming
Nair, P. G., Unnikrishnan, B. S., Vijayan, V. V., Howlett, S. E., Cullis, P. R., & Gujar, S. A. (2026) · ACS Nano · doi:10.1021/acsnano.5c18638 · Cited by 2
Prevention of neuroinfectious-diseases: high impact of vaccination programs – but the potential is not maxed out yet
Klein, M., Schöls, M., Tumani, H., Meyding-Lamadé, U., Decker, J., Maschke, M., & Wagner, J. N. (2026) · Neurological Research and Practice · doi:10.1186/s42466-026-00489-1 · Cited by 1
Immunosenescence as a driver of the transition from frailty to multimorbidity
Qiu, R., Zhang, D., & Feng, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1810241 · Cited by 2
Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: a randomised controlled trial
Harris, R., Thirard, R., McBrien, C., Middleditch, A., Chadwick, D., Jackson, J. K., Moran, E., Perry, J., Payne, R. A., Goodman, A. L., et al. (2026) · Journal of Infection · doi:10.1016/j.jinf.2026.106784 · Cited by 1
From awareness to action: Overcoming knowledge gaps and enhancing herpes zoster vaccination counseling among Chinese rheumatologists – Results from a nationwide survey
Geng, Y., Yang, Y., Lu, B., Xie, W., Wang, Y., & Zhang, Z. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2678679 · Cited by 1
Vaccination for Older Adults in India: Position Statement of the Indian Academy of Geriatrics
Singhal, S., Dewangan, G. C., Mehta, P. K., Viggeswarpu, S., Dey, A. B., & Gunasekaran, V. (2026) · Journal of The Indian Academy of Geriatrics · doi:10.4103/jiag.jiag_42_26 · Cited by 1
Advances in respiratory syncytial virus therapeutics: A comprehensive review of small-molecule inhibitors, monoclonal antibodies, and vaccines
Bai, G., Huang, X., & He, Y. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119092 · Cited by 1
KA101 outperforms other clinical adjuvants in inducing balanced Th1/Th2 immunity and robust B cell responses to varicella-zoster virus glycoprotein E
Quan, Y., Zhang, S., Wang, W., Wang, Y., Xu, K., Wang, K., Wan, W., & Nie, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1849099 · Cited by 1
Clinical Effectiveness of the Recombinant Zoster Vaccine for Preventing Herpes Zoster in Individuals With Kidney Transplants: A Retrospective Cohort Study
Kwon, K., Lim, S. M., Chang, E., Bae, S., Kwon, H., Jung, J., Kim, M. J., Shin, S., Chong, Y. P., Kim, Y. H., et al. (2026) · Transplant Infectious Disease · doi:10.1111/tid.70300 · Cited by 1
Trained Immunity in Childhood Vaccination
Cai, C., Hossenbaccus, L., & Kaufmann, E. (2026) · Acta Paediatrica · doi:10.1111/apa.70751 · Cited by 1

Authors: Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., Vanden Abeele, C., Vesikari, T., Watanabe, D., Zahaf, T., Ahonen, A., Athan, E., Barba-Gomez, J. F., Campora, L., de Looze, F., Downey, H. J., Ghesquiere, W., Gorfinkel, I., Korhonen, T., Leung, E., McNeil, S. A., Oostvogels, L., Rombo, L., Smetana, J., Weckx, L., Yeo, W., & Heineman, T. C.
Affiliations: The University of Sydney (AU)
Uppsala University (SE)
ORCID: Cunningham, Anthony L.
Lal, Himal
Hwang, Shinn-Jang
Godeaux, Olivier
Levin, Myron J.
McElhaney, Janet E.
Watanabe, Daisuke
Zahaf, Toufik
Athan, Eugene
de Looze, Ferdinandus
Gorfinkel, Iris
McNeil, Shelly A.
Oostvogels, Lidia
Rombo, Lars
Smetana, Jan
Weckx, Lily
Yeo, Wilfred
Heineman, Thomas C.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2016-09-15
Volume: 375
Issue: 11
Pages: 1019-1032
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1603800
OpenAlex: W2519957152
Cited by: 1,070
References: 31
Citations by year: 2026: 96 · 2025: 124 · 2024: 107 · 2023: 97 · 2022: 91 · 2021: 120 · 2020: 94 · 2019: 117 · 2018: 138 · 2017: 75 · 2016: 11
FWCI: 106.61
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Research Online (University of Wollongong) (submittedVersion)
Figshare (submittedVersion, cc-by)
CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
Funders: Bristol-Myers Squibb
Pfizer
AstraZeneca
Sanofi
Novo Nordisk
Astellas Pharma
H. Lundbeck A/S
Sanofi Pasteur
Topics: Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
Keywords: herpes zoster, postherpetic neuralgia, vaccine efficacy, older adults, AS01B adjuvant, vaccine safety, herpes zoster incidence, vaccine adverse events, immunosenescence, immunogenicity
MeSH terms: Aged, Aged, 80 and over, Double-Blind Method, Female, Herpes Zoster, Humans, Male, Middle Aged, Risk, Vaccines, Subunit, Neuralgia, Postherpetic, Herpes Zoster Vaccine, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks